Centene Corporation
CNC
$65.02
+1.37%
Centene Corporation is a managed care organization focused on government-sponsored healthcare programs, primarily Medicaid, Medicare, and individual health insurance exchanges, serving approximately 20 million medical members as of December 2025. As one of the largest Medicaid managed care providers in the United States, Centene differentiates itself through its scale and specialization in government-funded healthcare, with Medicaid comprising about 64% of its membership. The current investor narrative centers on the company's strategic pivot from membership growth toward profitability, highlighted by recent cost-cutting measures such as voluntary staff buyouts following a significant loss of Affordable Care Act exchange members. Additionally, the stock has experienced a remarkable recovery over the past year, driven by improved sector sentiment from favorable Medicare payment rate increases and a broader risk-on rally in healthcare stocks.…
CNC
Centene Corporation
$65.02
Related headlines
Investment Opinion: Should I buy CNC Today?
Centene is rated a Buy based on its strong turnaround momentum, attractive forward valuation, and favorable sector tailwinds. The consensus recommendation is 'Buy' with an average target price of $71.67, implying 6.2% upside. The stock's forward PE of 12.7x and PS ratio of 0.10x are well below sector averages, and Q1 2026 revenue growth of 7.1% YoY supports the recovery narrative. Free cash flow of $6.35 billion provides financial flexibility. Key risks include membership losses, high debt, and potential margin pressure. This rating would be upgraded if the stock pulls back to below $60, or downgraded if revenue growth decelerates below 5% or if the company reports another significant loss. Overall, the stock appears undervalued relative to its forward earnings potential.
Sign up to view all
CNC 12-Month Price Forecast
The AI assessment is bullish on Centene, driven by strong recent earnings recovery, attractive valuation, and favorable sector tailwinds. The company's ability to sustain profitability improvements and manage membership dynamics will be crucial. If the company continues to beat expectations, the stance could be upgraded to high confidence. Conversely, any significant operational setbacks would warrant a downgrade.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $71.67 and implied upside of +10.2% versus the current price.
Average Target
$71.67
0 analysts
Implied Upside
+10.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$56 - $85
Analyst target range
Centene is covered by 18 analysts, with a consensus recommendation of 'Buy' (mean rating of 2.33 on a scale where 1 is Strong Buy and 5 is Sell). The average target price is $71.67, implying approximately 6.2% upside from the current price of $67.47. The target range spans from a low of $56.00 to a high of $85.00, with the high target suggesting potential for further gains if the company successfully executes its profitability strategy and benefits from favorable Medicare payment rates. Recent institutional ratings have been predominantly neutral-to-positive, with firms like Wells Fargo, RBC Capital, and JP Morgan maintaining Equal Weight or Neutral stances, while Cantor Fitzgerald and Barclays remain Overweight, indicating a balanced but constructive outlook.
Bulls vs Bears: CNC Investment Factors
Centene presents a compelling turnaround story, with strong recent earnings recovery, attractive forward valuation, and favorable sector tailwinds from Medicare payment increases. The stock has already rallied 150% in the past year, reflecting investor optimism. However, the company faces significant challenges, including a negative trailing net margin, high debt levels, and membership declines in the ACA segment. The bull case is currently stronger, supported by improving fundamentals and analyst consensus, but the stock's proximity to its 52-week high and limited upside to analyst targets warrant caution. The key tension lies in whether Centene can sustain its profitability improvements and offset membership losses, which will determine if the stock can continue its upward trajectory.
Bullish
- Exceptional 1-Year Price Surge: CNC's stock has rallied 150.5% over the past year, vastly outperforming the S&P 500's 20.4% gain. This reflects strong investor confidence in the company's turnaround strategy and improved sector sentiment, particularly after the CMS Medicare payment rate increase.
- Strong Q1 2026 Earnings Recovery: In Q1 2026, Centene reported net income of $1.54 billion, a dramatic swing from the $6.63 billion loss in Q3 2025. The gross margin improved to 21.9% from 15.2% in Q4 2025, indicating successful cost management and operational efficiency gains.
- Attractive Forward Valuation: With a forward PE of 12.7x and a price-to-sales ratio of 0.10x, the stock is trading at a significant discount to the broader healthcare sector. Analysts project EPS of $9.06 for the next fiscal year, implying substantial earnings growth potential.
- Favorable Medicare Payment Increase: The CMS announced a larger-than-expected 2027 Medicare Advantage payment increase, boosting revenue visibility across the managed care sector. This directly benefits Centene's Medicare segment, which is a key growth area.
Bearish
- Negative Trailing Net Margin: The trailing twelve-month net margin is -3.4%, reflecting the impact of prior reserve charges and operational losses. Despite recent improvements, the company has not yet demonstrated sustained profitability on a trailing basis.
- High Debt-to-Equity Ratio: With a debt-to-equity ratio of 0.94, Centene carries a significant debt load. This increases financial risk, especially if interest rates remain elevated or if the company faces unexpected operational challenges.
- Membership Decline in ACA Segment: Centene has experienced a significant loss of Affordable Care Act exchange members, leading to voluntary staff buyouts. This membership slump could pressure near-term revenue growth and signal competitive challenges in the individual exchange market.
- Stock Near 52-Week High: At $67.47, the stock is trading near its 52-week high of $69.36, leaving limited upside to the average analyst target of $71.67 (6.2% upside). This suggests that much of the positive news may already be priced in.
CNC Technical Analysis
Centene's stock has exhibited a powerful sustained uptrend over the past year, with a 1-year price change of +150.5%, significantly outperforming the S&P 500's +20.4% gain. The current price of $67.47 sits near the upper end of its 52-week range, at approximately 97% of the range (calculated as (67.47 - 27.76) / (69.36 - 27.76) = 0.966), indicating strong momentum and bullish sentiment. This positioning near the 52-week high of $69.36 suggests the market is rewarding the company's operational improvements and sector tailwinds, though it also raises the risk of short-term overextension.
Beta
1.10
1.10x market volatility
Max Drawdown
-32.7%
Largest decline past year
52-Week Range
$28-$69
Price range past year
Annual Return
+125.7%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | -1.3% | +2.5% |
| 3m | +9.9% | +2.7% |
| 6m | +50.4% | +11.1% |
| 1y | +125.7% | +20.5% |
| ytd | +55.6% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Centene's revenue trajectory shows steady growth, with the most recent quarter (Q1 2026) reporting revenue of $49.94 billion, a 7.1% year-over-year increase. This growth is driven primarily by the Medicaid segment, which contributed $39.21 billion in revenue, followed by the Commercial segment at $9.56 billion. However, the company has experienced significant earnings volatility, with net income swinging from a loss of $6.63 billion in Q3 2025 to a profit of $1.54 billion in Q1 2026, reflecting the impact of prior reserve charges and ongoing operational adjustments. The gross margin improved to 21.9% in Q1 2026 from 15.2% in Q4 2025, indicating better cost management, though the trailing twelve-month net margin remains negative at -3.4%.
Quarterly Revenue
$49.9B
2026-03
Revenue YoY Growth
+7.1%
YoY Comparison
Gross Margin
21.9%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Given the negative trailing twelve-month net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, currently at 0.10x, which is exceptionally low compared to the broader healthcare sector. The forward PE ratio of 12.7x suggests the market expects a significant earnings recovery, as analysts project EPS of $9.06 for the next fiscal year. This wide gap between trailing losses and forward profitability indicates that investors are pricing in a substantial turnaround, which is supported by the company's improving quarterly results and cost-cutting initiatives.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant, with a debt-to-equity ratio of 0.94 indicating a high leverage level. The company's trailing twelve-month net margin is -3.4%, reflecting past losses, though Q1 2026 showed a positive net income of $1.54 billion. Free cash flow is strong at $6.35 billion, but the negative trailing EPS of -$0.33 and the need to service debt could strain liquidity if operational performance falters. Revenue concentration in Medicaid (64% of membership) exposes the company to government funding changes and regulatory shifts.
FAQ
Key risks include financial risks from high debt (debt-to-equity of 0.94) and negative trailing margins, competitive risks from membership losses in the ACA segment, and macro risks from regulatory changes in Medicaid and Medicare. The stock's beta of 1.105 indicates higher volatility than the market. The most severe risk is a failure to sustain profitability, which could lead to a decline toward the 52-week low of $27.76.
The 12-month forecast is moderately bullish, with a base case target of $71.67 (6.2% upside), a bull case target of $85 (26% upside), and a bear case target of $56 (-17% downside). Probabilities are 50% base, 30% bull, and 20% bear. The most likely scenario is continued gradual recovery, supported by improving margins and favorable sector trends.
CNC is undervalued relative to its forward earnings potential, with a forward PE of 12.7x and a PS ratio of 0.10x, both well below sector averages. The market is pricing in a significant earnings recovery, as evidenced by the gap between trailing losses and projected EPS of $9.06. Compared to its own history, the stock is trading near the high end of its 52-week range, but the valuation metrics suggest it is still attractively priced for the growth expected.
CNC is a good buy for investors with a medium-to-high risk tolerance, given its strong turnaround momentum and attractive forward valuation. The stock has rallied 150% in the past year, and analysts see 6.2% upside to the average target of $71.67. However, the stock is near its 52-week high, and the negative trailing net margin of -3.4% poses a risk. A pullback to below $60 would offer a better entry point.
CNC is more suitable for long-term investment, given its turnaround nature and the time needed for earnings recovery to materialize. The stock's beta of 1.105 and recent volatility suggest short-term trading could be risky. A minimum holding period of 12-18 months is recommended to allow the company to execute its profitability strategy and for the market to recognize the value.